9 ms·
I would like to thank you all for reading my article. I have spent most of my life thus far in technology, coding since I was 10. This was back when the TI99/
by ForHumanity 14y ago
I would like to thank you all for reading my article. I have spent most of my life thus far in technology, coding since I was 10. This was back when the TI99/4a was news and 32k was alot of elbo room.
About 14 years ago I decided to study Neuroscience so I could build a better human/computer interface. Little did I know that I was igniting a latent passion for the biosciences that would consume my free time hence forth and thousands of dollars.
I related quickly to the biosciences because molecular physiology bears a striking semblance to computer/software architecture.
Now, I have had an article published on my proposed targeted cancer therapeutic (http://blog.readingthinkingandwriting.com/?p=411 http://blog.readingthinkingandwriting.com/?p=411) and I have turned my focus to Dr. Rider's work at MIT to end viral infections of all types.
http://blog.readingthinkingandwriting.com/?p=500 http://blog.readingthinkingandwriting.com/?p=500
The expectations of Dr. Rider with regard to targets of DRACO include HIV, and I would ask that anyone who reads my article pays close attention. I have attempted to relay the science behind the reason I have concluded that Dr. Rider's work will be historic. And I hope I have done just that, though I apologize for where I've failed.
Tissue penetration is addressed by the mouse models... and, from the way our immune system operates. Where an infection resides, molecules are spread that increase vascular permeability and constrict draining vessles thus concentrating blood volume. This is essentially how any medicine acts with specifitcity to the location of infection and what assures DRACO will hit target cells.
Further research in Dr. Rider's lab has shown that not only does DRACO succesfully induce the destruction of infected cells, but that it also reduces the viral titres (quantity of the virus).
I'm happy to answer any further questions.